FIGURE 1.
68Ga-PSMA-11 PET demonstrates increased PSMA expression in prostate cancer xenografts with inhibition of AR. (A) Ratio of SUVmean at day 7 to day 0 increased an average of 72% with orchiectomy and 105% with ARN-509 compared with vehicle. (B) Visual assessment of 68Ga-PSMA-11 PET demonstrates clear increase in uptake in xenografts in response to ARN-509 (middle row) and orchiectomy (bottom row), compared with controls treated with vehicle (top row). *P = 0.007. **P = 0.013. ID = injected dose; ROI = region of interest; RX = treatment.